Shares of Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) have been assigned an average recommendation of “Buy” from the sixteen ratings firms that are currently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation and twelve have given a buy recommendation to the company. The average twelve-month price objective among analysts that have updated their coverage on the stock in the last year is $67.50.

AERI has been the topic of several recent research reports. Canaccord Genuity restated a “buy” rating on shares of Aerie Pharmaceuticals in a research report on Friday, September 22nd. Mizuho restated a “buy” rating and set a $70.00 target price on shares of Aerie Pharmaceuticals in a research report on Monday, October 16th. Zacks Investment Research downgraded Aerie Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, October 10th. Cantor Fitzgerald restated a “buy” rating and set a $62.00 target price on shares of Aerie Pharmaceuticals in a research report on Wednesday, October 11th. Finally, Stifel Nicolaus restated a “buy” rating and set a $70.00 target price on shares of Aerie Pharmaceuticals in a research report on Friday, July 28th.

WARNING: This story was originally posted by American Banking News and is the property of of American Banking News. If you are reading this story on another site, it was stolen and republished in violation of U.S. & international trademark & copyright laws. The original version of this story can be viewed at https://www.americanbankingnews.com/2017/11/02/aerie-pharmaceuticals-inc-aeri-receives-consensus-recommendation-of-buy-from-analysts.html.

Aerie Pharmaceuticals (NASDAQ:AERI) last posted its earnings results on Tuesday, August 1st. The company reported ($0.82) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.84) by $0.02.

Several institutional investors have recently added to or reduced their stakes in AERI. UBS Asset Management Americas Inc. increased its holdings in shares of Aerie Pharmaceuticals by 97.3% in the first quarter. UBS Asset Management Americas Inc. now owns 12,430 shares of the company’s stock worth $564,000 after purchasing an additional 6,130 shares during the period. Karp Capital Management Corp bought a new position in shares of Aerie Pharmaceuticals in the first quarter worth $213,000. Parametric Portfolio Associates LLC increased its holdings in shares of Aerie Pharmaceuticals by 5.8% in the first quarter. Parametric Portfolio Associates LLC now owns 68,398 shares of the company’s stock worth $3,102,000 after purchasing an additional 3,739 shares during the period. FMR LLC increased its holdings in shares of Aerie Pharmaceuticals by 178.7% in the first quarter. FMR LLC now owns 320,500 shares of the company’s stock worth $14,535,000 after purchasing an additional 205,500 shares during the period. Finally, Teachers Advisors LLC increased its holdings in shares of Aerie Pharmaceuticals by 5.1% in the first quarter. Teachers Advisors LLC now owns 49,726 shares of the company’s stock worth $2,255,000 after purchasing an additional 2,402 shares during the period. 94.71% of the stock is currently owned by hedge funds and other institutional investors.

Aerie Pharmaceuticals Company Profile

Aerie Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company’s product candidates include Rhopressa (netarsudil ophthalmic solution) 0.02% (Rhopressa), and Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% (Roclatan).

Analyst Recommendations for Aerie Pharmaceuticals (NASDAQ:AERI)

Receive News & Ratings for Aerie Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.